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Supplemental Figure 1. Sex-based overall survival and disease free survival analyses of 
TCGA LGG Datasets.  There are no sex-differences in A. overall survival (OS) or B. disease 






Supplemental Figure 2. There are few sex differences in expression of 36 glucose 
metabolism genes involved in hexose transport, glycolysis, and monocarboxylate transport. 
A. Male (blue) and female (pink) RSEM values are plotted together for each gene. Only 2 genes 
(HK1 and LDHB) display subtle but statistically significant differences in expression between 
males and females.  Genes arranged from lowest to highest median RSEM expression.  B. Sex-
specific Z-score transformation of RSEM values reveals no sex differences in gene expression. 






Supplemental Figure 3. Glycolytic tumor samples are enriched for astrocytomas.  
Enrichment of histopathologic and WHO grade classifiers were assessed in the glycolytic and 
non-glycolytic groups. Oligoastrocytomas and oligodendrogliomas are less abundant in the 
glycolytic group where astrocytomas are enriched in the glycolytic group. Significance 











Supplemental Figure 4. Glycolysis-based stratification correlates with genomic alterations 
in gliomas.  A. Progression from the genomic type 1 (1p/19q co-deletion/ IDH mutant) LGG to 
the more aggressive genomic type 3 (IDH wildtype) LGG enriches for the glycolytic tumor 
classifier. B. Genomic alterations significantly depleted in the glycolytic group include FUBP1, 
CIC, IDH mutations and 1p/19q co-deletion). Alterations significantly enriched in the glycolytic 
group include PTEN, EGFR, and NF1 mutations. TP53 and ATRX were not enriched in either 
group. Significance calculated using the two-tailed Fisher exact test. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  
 
 
Supplemental Figure 5. Glycolysis stratifies males independently of TP53 and ATRX status 
in gliomas.  A.  TP53 mutant samples. B. TP53 wildtype samples. C. ATRX mutant samples. D. 
ATRX wildtype samples. p-values were calculated using the log-rank test. Numbers in 









Supplemental Figure 6. Glycolytic metabolites are not significantly different between males 
and females with grade 2 gliomas. p-values were calculated using the two-tailed Student’s, t-
test. Data are represented as the mean + 95% C.I. 
 
 
Supplemental Figure 7. Glycolytic metabolites stratify males but not females with grade 2 
gliomas. Fructose-6-phosphate (F-6-P) stratifies A. male but not B. female gliomas. 
Dihydroxyacetone phosphate (DHAP) stratifies C. male but not D. female gliomas. p-values 
were calculated using the log-rank test. Numbers in parentheses refer to number of deaths / total 













Supplemental Table 1. Mean gene expression Z-score values for 36 glycolytic genes in male 















PGK1 -0.251090882 1.985187288 -0.214404549 1.601263323 
GPI -0.224738361 1.776837669 -0.257712031 1.941684189 
LDHA -0.224635066 1.776020994 -0.129156407 0.997340487 
TPI1 -0.217632393 1.720656108 -0.180050541 1.357309715 
SLC2A3 -0.20728892 1.638878024 -0.229728886 1.732651284 
HK1 -0.196008634 1.549693261 -0.274679296 2.059720466 
ENO2 -0.184465253 1.458428409 -0.283740943 2.105656386 
ENO1 -0.180196439 1.424678093 -0.099304355 0.78629729 
GAPDH -0.174307468 1.378118418 -0.11417666 0.858473082 
ALDOA -0.161913515 1.280128726 -0.203041727 1.541344557 
PKM2 -0.160385865 1.268050746 -0.17233714 1.276187244 
PGAM1 -0.132677239 1.048979423 -0.221259066 1.650484798 
PKLR -0.128093139 1.012736379 -0.087614677 0.659159434 
SLC16A3 -0.127423129 1.007439117 0.039009844 -0.261043457 
PFKP -0.126394921 0.999309842 -0.260120558 1.972898623 
HK3 -0.110588762 0.874342398 0.028824933 -0.195899608 
PFKL -0.095587628 0.755739686 -0.069100829 0.53573822 
SLC2A1 -0.073610802 0.581985403 -0.015020757 0.073874619 
SLC16A8 -0.072578737 0.573825636 -0.104359164 0.784722618 
GCK -0.055825886 0.441373408 -0.015307403 0.137992407 
HK2 -0.054148047 0.428107994 0.074621381 -0.516890009 
SLC2A2 -0.051389924 0.40630159 0.010698048 -0.062200703 
SLC16A1 -0.027820355 0.219954681 0.083839343 -0.605444771 
PGK2 -0.019876106 0.157145468 -0.001724718 0.01899839 
SLC16A7 -0.015353848 0.121391357 -0.076115078 0.505629845 
ALDOB -0.000796865 0.006300211 -0.068786178 0.533986296 
LDHAL6B -5.22E-06 4.13E-05 -0.008959949 0.096456034 
LDHC 0.000532518 -0.004210218 0.006328065 -0.033848191 
PFKM 0.000552602 -0.004369011 -0.104045365 0.748761714 
SLC2A5 0.005684456 -0.044942731 0.073780488 -0.517104992 
SLC2A4 0.010205535 -0.080687513 0.035009697 -0.234868712 
LDHB 0.01382981 -0.109341938 0.061729914 -0.467884066 
PGAM2 0.014342112 -0.113392322 0.045690772 -0.327183814 
ALDOC 0.021763087 -0.172064409 -0.01686641 0.15647868 
GAPDHS 0.030218655 -0.238916244 -0.002435995 0.055912094 
ENO3 0.050185012 -0.396775247 0.068148665 -0.472910228 
 
 
Supplemental Table 2. Optimization of Z-score sliding threshold for sex differences in 
glycolysis. NA: Could not be defined due to insufficient sample size or lack of definable median 
OS. Significant p-values are bolded with asterisks.  
 

















0 98.16 NA NA NA NA 
0.25 98.16 NA NA NA NA 
0.5 79.93 NA NA 0.3294 NA 
0.75 79.93 138.93 -59 0.0625 0.2953 
1 74.97 138.9 -63.93 0.0307* 2.366 
1.25 74.97 138.9 -63.93 0.0481* 1.968 
1.5 74.97 138.9 -63.93 0.0053** 2.255 
1.75 62.91 138.9 -75.99 0.0018** 2.46 
2 62.91 105.1 -42.19 0.001** 2.044 
2.25 50.1 105.1 -55 0.0031** 1.984 
2.5 62.91 105.1 -42.19 0.0357* 1.633 
2.75 62.91 98.16 -35.25 0.0821 1.422 
3 62.91 98.16 -35.25 0.0703 1.423 
      

















0 78.15 NA NA NA NA 
0.25 78.15 NA NA 0.7421 NA 
0.5 78.15 NA NA 0.5285 NA 
0.75 78.15 NA NA 0.288 2.737 
1 78.15 NA NA 0.1333 2.801 
1.25 75.1 114 -38.9 0.4169 1.418 
1.5 75.1 114 -38.9 0.4953 1.269 
1.75 75.1 94.45 -19.35 0.9541 0.9828 
2 78.15 94.45 -16.3 0.9538 1.017 
2.25 78.15 94.45 -16.3 0.3769 0.7872 
2.5 87.39 78.15 9.24 0.4323 0.8079 
2.75 93.13 73.42 19.71 0.491 0.8262 




Supplemental Table 3. Survival analysis of significant glycolytic Genes using the Z = 1.75 
threshold. Undefined:  lack of definable median OS. Significant p-values are bolded with 
asterisks. 
 







value HR (95% CI) 
GAPDH 36.33 105.1 < 0.0001**** 4.078 (4.661 to 59.90) 
LDHA 18.43 98.16 < 0.0001**** 6.321 (25.33 to 720.8) 
PGK1 24.38 98.16 0.0002*** 4.199 (4.277 to 105.6) 
SLC16A3 24.38 98.16 < 0.0001**** 4.803 (6.639 to 203.0) 
HK3 26.74 98.16 0.0004*** 6.248 (10.13 to 2672) 
PFKL 24.38 98.16 0.0018** 3.789 (2.781 to 79.71) 
SLC2A5 37.35 98.16 0.0485* 2.261 (1.013 to 11.12) 
GCK 22.84 98.16 < 0.0001**** 6.12 (15.92 to 1097) 
GPI 24.9 98.16 0.0005*** 3.645 (3.007 to 47.82) 
PGAM2 28.94 98.16 0.043* 3.088 (1.076 to 55.77) 
SLC16A8 21.29 98.16 < 0.0001**** 7.287 (22.03 to 9022) 
     







value HR (95% CI) 
GAPDH Undefined 78.15 0.2576 undefined 
LDHA 133.6 78.15 0.4288 0.7023 (0.3199 to 1.589) 
PGK1 Undefined 78.15 0.8706 0.8506 (0.1374 to 5.345) 
SLC16A3 51.84 93.13 0.1017 1.913 (0.8468 to 6.650) 
HK3 33.94 93.13 0.0073** 3.264 (1.796 to 40.33) 
PFKL Undefined 78.15 0.3386 undefined 
SLC2A5 63.5 93.13 0.6428 1.22 (0.4967 to 3.120) 
GCK 29.11 87.39 0.181 1.834 (0.6954 to 7.571) 
GPI 75.1 146 0.2405 0.441 (0.2075 to 1.479) 
PGAM2 54.73 87.39 0.4424 1.723 (0.3308 to 12.73) 













expressed in the same 
sample Number of Male Samples Number of Female Samples 
0 220 150 
1 38 38 
2 10 23 
3 3 8 
4 7 7 
5 1 0 
6 2 1 
7 1 0 
8 1 0 
9 0 0 
10 0 0 
11 0 0 
 
 
 
 
 
 
 
 
